• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
PharmaLeaders: Generic Manufacturers Benchmark Report - Financial Benchmarking & Competitive Analysis of the Leading Generic Players in 2013 - Product Image

PharmaLeaders: Generic Manufacturers Benchmark Report - Financial Benchmarking & Competitive Analysis of the Leading Generic Players in 2013

  • Published: March 2013
  • Region: Global
  • 105 Pages
  • GlobalData

FEATURED COMPANIES

  • Actavis
  • Covidien
  • Dr. Reddy's
  • Hospira
  • Mylan
  • Pharmstandard
  • MORE

"PharmaLeaders: Generic Manufacturers Benchmark Report - Financial Benchmarking & Competitive Analysis of the Leading Generic Players in 2013" applies Our proprietary ranking methodology to compare the competitive position of 30 generic pharmaceutical companies across various markets on 12 financial metrics. The performances of these companies are analyzed based on financial performance, cost-containment, capital structure, and efficiency to illustrate the different strategies these companies are using to increase shareholder value and capture market share from branded pharmaceuticals manufacturers. In addition to the financial metrics, this report presents SWOT analyses of the major players, and describes the operations strategy of these companies.

Throughout the report, Our analysts provide you with expert insight, expanding on each strategy and factor discussed, with the aim of providing you with the tools needed for making informed business decisions.

Scope

- The report provides analysis of the key drivers and trends shaping the global generics industry.
- The report identifies the key generic players in various markets, including a special focus on emerging READ MORE >

1 Tables & Figures
1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 Report Scope
2.2 Upcoming Related Reports
2.3 Recently Published Reports
2.4 GlobalData's Benchmarking Methodology

3 GlobalData Benchmark Rankings
3.1 Sun Pharmaceuticals Emerges as Generics Leader

4 Financial Management
4.1 Competitive Framework
4.2 Overview
4.3 Financial Management: Heat Map
4.4 Financial Metrics
4.4.1 Revenue Leaders
4.4.2 Revenue Laggards
4.4.3 Revenue Growth Leaders
4.4.4 Revenue Growth Laggards
4.4.5 Operating Income Leaders
4.4.6 Operating Income Laggards
4.4.7 Operating Income YTY Growth Leaders
4.4.8 Operating Income YTY Growth Laggards
4.4.9 Operating Margin Leaders
4.4.10 Operating Margin Laggards

5 Expense Management
5.1 Competitive Framework
5.2 Overview
5.3 Expense Management: Heat Map
5.4 Expense Metrics
5.4.1 SG&A Spending Leaders
5.4.2 SG&A Spending Laggards
5.4.3 SG&A YTY Change Leaders
5.4.4 SG&A YTY Change Laggards
5.4.5 Operating Expense Leaders
5.4.6 Operating Expense Laggards

6 Capital Management
6.1 Competitive Framework
6.2 Overview
6.3 Competitive Framework: Heat Map
6.4 Capital Management Metrics
6.4.1 Debt-to-Assets Leaders
6.4.2 Debt-to-Assets Laggards
6.4.3 Cash Ratio Leaders
6.4.4 Cash Ratio Laggards
6.4.5 ROI Leaders
6.4.6 ROI Laggards

7 Key Players
7.1 Strategic Analysis of Leading Generics Players
7.1.1 Sun Pharmaceuticals: The Benchmark Leader
7.1.2 Sandoz
7.1.3 Pharmstandard
7.1.4 Teva Pharmaceuticals
7.1.5 Actavis
7.1.6 Mylan
7.1.7 Ranbaxy
7.1.8 Dr. Reddy's
7.1.9 Covidien
7.1.10 Hospira

8 Outlook
8.1 Leverage Improvement will Significantly Alter 2013 Benchmark Rankings
8.2 Generic Manufacturers in Emerging Markets will continue to Challenge for Top Spots

9 Appendix
9.1 Bibliography
9.2 Abbreviations
9.3 Research Methodology
9.3.1 Coverage
9.3.2 Secondary Research
9.3.3 Expert Panel Validation
9.4 About the Authors
9.4.1 Analyst
9.4.2 Director of Healthcare Industry Dynamics
9.4.3 Global Head of Healthcare Research and Consulting
9.5 About the Industry Dynamics Team
9.6 About Us
9.7 Contact Us
9.8 Disclosure Information
9.9 Disclaimer

1.1 List of Tables
Table 1: GlobalData Benchmark Rankings, FY2012
Table 2: Top 15 Companies FM Composite Scores and Overall FM Score, 2012
Table 3: Bottom 15 Companies' FM Composite Scores and Overall FM Score, 2012
Table 4: FY2012 Top Three Revenue Leaders
Table 5: FY2012 Top Three Revenue Laggards
Table 6: FY2012 Top Three Revenue Growth Leaders
Table 7: FY2012 Top Three Revenue Growth Laggards
Table 8: FY2012 Top Three Operating Income Leaders
Table 9: FY2012 Top Three Operating Income Laggards
Table 10: FY2012 Top Three YTY Operating Income Growth Leaders
Table 11: FY2012 Top Three YTY Operating Income Growth Laggards
Table 12: FY2012 Top Three Operating Margin Leaders
Table 13: FY2012 Top Three Operating Margin Laggards
Table 14: Top 15 Companies' EM Composite Scores and Overall EM Score, 2012
Table 15: Bottom 15 Companies' EM Composite Scores and Overall EM Score, 2012
Table 16: FY2012 Top SG&A Spending Leaders as a Percentage of Revenue
Table 17: FY2012 Top R&D Spending Laggards as a Percentage of Revenue
Table 18: FY2012 Top SG&A YTY Change Leaders
Table 19: FY2012 Top SG&A YTY Change Laggards
Table 20: FY2012 Top Operating Expense Leaders as a Percentage of Revenue
Table 21: FY2012 Top Operating Expense Laggards as a Percentage of Revenue
Table 22: Top 15 Companies' CM Composite Scores and Overall CM Score, 2012
Table 23: Bottom 15 Companies' CM Composite Scores and Overall CM Score, 2012
Table 24: FY2012 Top Debt-to-Assets Leaders
Table 25: FY2012 Debt-to-Assets Laggards
Table 26: FY2012 Cash Ratio Leaders
Table 27: FY2012 Cash Ratio Laggards
Table 28: FY2012 ROI Leaders
Table 29: FY2012 ROI Laggards

1.2 List of Figures
Figure 1: Generics Manufacturing Landscape Assessment – FY2012 Corporate Revenue Growth vs. Operating Margin
Figure 2: Generics Manufacturing Landscape Assessment – FY2012 Generics Sales Growth vs. Operating Margin
Figure 3: FY2011 and FY2012 Leading Generic Pharmaceutical Companies by Revenue
Figure 4: FY2012 Leading Generic Pharmaceutical Companies by YTY Revenue Growth
Figure 5: FY 2011 and FY2012 Leading Generic Pharmaceutical Companies by Operating Income ($m)
Figure 6: FY2012 Leading Generic Pharmaceutical Companies by YTY Operating Income Growth
Figure 7: FY 2011 and FY2012 Leading Generic Pharmaceutical Companies by Operating Margin
Figure 8: Top 30 Generic Pharmaceutical Landscape Assessment – FY2012 SG&A Expense vs. Operating Expense as a Percentage of Revenue
Figure 9: FY 2011 and FY2012 Leading Generic Pharmaceutical Companies by SG&A Spending ($m)
Figure 10: FY 2011 and FY2012 Leading Generic Pharmaceutical Companies by SG&A Spending as a Percentage of Revenue
Figure 11: FY2012 Leading Generic Pharmaceutical Companies by SG&A Spending as a Percentage of Revenue, YTY Change
Figure 12: FY2011 and FY2012 Leading Generic Pharmaceutical Companies by Operating Expense as a Percentage of Revenue
Figure 13: FY2011 and FY2012 Leading Generic Pharmaceutical Companies by Debt-to-Assets Ratio
Figure 14: FY 2011 and FY2012, Leading Generic Pharmaceutical Companies by Cash Ratio
Figure 15: FY 2011 and FY2012 Leading Generic Pharmaceutical Companies by ROI
Figure 16: Sun Pharmaceuticals: SWOT Analysis
Figure 17: Sandoz: SWOT Analysis
Figure 18: Pharmstandard: SWOT Analysis
Figure 19: Teva Pharmaceuticals: SWOT Analysis
Figure 20: Teva Generics Sales in US vs. Rest-of-World (ROW)1, 2009–2012
Figure 21: Actavis: SWOT Analysis
Figure 22: Mylan: SWOT Analysis
Figure 23: Ranbaxy: SWOT Analysis
Figure 24: Dr. Reddy's: SWOT Analysis
Figure 25: Covidien: SWOT Analysis
Figure 26: Hospira: SWOT Analysis

Sun Shines on Indian Generics Manufacturers

India is becoming a key market for generic medicines, and pharmaceutical companies must compete and grow their revenues there to have a shot at claiming the title of industry leader, according to a new report by research and consulting firm The authors.

The new report* states that India-based trio of Glenmark, Sun Pharmaceuticals, and Ranbaxy topped the charts in terms of year to year (YTY) revenue growth in 2012, with 71.6%, 47.6%, and 32.9% respectively. Although larger generic manufacturers – Teva, Sandoz, and Mylan – emerged as revenue leaders in 2012, with sales of US$10.4 billion, US$8.7 billion, and US$5.8 billion respectively, their performance in 2013 may vary, as other competitors, including Sun Pharmaceuticals step up efforts to grow their share of the global generics market.

Domestic players in India are currently experiencing massive growth YTY revenue as they continue to leverage many decades of reverse engineering experience. The authors believes that Indian generic manufacturers have become the go-to companies when it comes to low-cost generics, as affirmed by the entrance of pharmaceutical giants such as Gilead and Pfizer into generic manufacturing agreements with them in 2012.

Sun Pharmaceuticals holds a strong position in the Indian generics market, leading the pack in terms of operating margin and revenue growth, although the company's sales figures currently pale in comparison with larger companies. The company's domestic revenues increased by 44.9% from US$586.5m in 2011 to US$865.9m in 2012, as market shares were captured from competitors. Sun Pharmaceuticals will have to continually compete with other Indian generic manufacturers, including Ranbaxy, Dr. Reddy's and Cipla, as well as the influx of foreign generic and branded pharmaceutical companies. This rivalry, which is likely to focus on the price sensitivity of domestic consumers, could potentially decrease the company's profit margins. Nevertheless, The authors anticipates that Sun will be one to watch in 2013, as the company aims to rub shoulders with companies in the top echelon of generics manufacturing.

Mylan benefited from aggressive growth in the Indian market during 2012, as the company's generics business flourished in the country. This resulted from an increase in sales of anti-retroviral (ARV) finished dosage form (FDF) generic products, used in the treatment of HIV/AIDS. Mylan is currently one of the world's largest API manufacturers, particularly in APIs used in manufacturing generic ARV therapies for HIV/AIDS treatment. The company has total control over its supply chain, and so can effectively control cost and quality – two crucial requirements in the pharmaceuticals business.

Similarly, Teva and Sandoz are stepping up efforts to grow their revenues outside established markets. Sandoz, in particular, needs to gain ground in emerging markets, as 80% of its generic pharmaceutical sales currently come from the US and Europe, leaving the company exposed to the current pricing pressures and budget deficits in these markets.

Actavis
Covidien
Dr. Reddy's
Hospira
Mylan
Pharmstandard
Ranbaxy
Sandoz
Sun Pharmaceuticals
Teva Pharmaceuticals

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos